Structural mutations in the p53 gene are seen in virtually every form
of human cancer. To determine whether such mutations are important for
initiating tumorigenesis, we have been studying hepatocellular carcin
oma, in which most cases are associated with chronic hepatitis B virus
infections. Using a transgenic mouse model where expression of a sing
le HBV gene product, the HBx protein, induces progressive changes in t
he liver, we show that tumour development correlates precisely with p5
3 binding to HBx in the cytoplasm and complete blockage of p53 entry i
nto the nucleus. Analysis of tumour cell DNA shows no evidence for p53
mutation, except in advanced tumours where a small proportion of cell
s may have acquired specific base substitutions. Our results suggest t
hat genetic changes in p53 are late events which may contribute to tum
our progression.